Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Shares Of Qorvo Inc (QRVO) Tumble After Weak Guidance, Hedge Funds Growing Wary?

Page 1 of 2

Semiconductor devices manufacturer Qorvo Inc (NASDAQ:QRVO) issued weak guidance for the company’s fiscal second quarter of 2016 in the after-hours of trading yesterday, pushing shares down by 13.30% in pre-market trading this morning. According to the chipmaker’s statement, it expects to post earnings per share in the range of $1.05 – $1.15, on revenue of between $690 million and $710 million. Wall Street analysts expected the company to post earnings per share of $1.28 on revenue of $741.5 million for the second quarter, which ends in September. For the fiscal first quarter of 2016, which Qorvo Inc (NASDAQ:QRVO) also reported yesterday, the company posted earnings per share of $1.09, beating the analysts’ consensus estimate of $1.03. The revenue for the period was $673.60 million while analysts expected $664.73 million. The released guidance comes as a big surprise, as there is nothing unusual expected in the industry to warrant such a variation. Wall Street’s reaction is a clear indication that the guidance wasn’t expected. Qorvo Inc was formed in January of this year after a $1.55 billion merger between RF Micro Devices and TriQuint Semiconductor.

motherboard, circuit, chip, Intel, Micron, Qualcomm, AMD

Going into the second quarter of 2015, a total of 29 hedge funds from our database were long in the stock, with aggregate investments valued at $793.48 million. During the first quarter, the stock managed to register a 13.21% gain, which was impressive, considering the industry has been slow. Qorvo Inc (NASDAQ:QRVO), however, couldn’t maintain that kind of performance in the second quarter, only pulling a 0.72% gain. It’s for this reason that a number of hedge funds may have opted out. However, an overall view of the stock shows that many hedge funds still remained bullish on the stock, and the company’s performance in the fiscal first quarter was vindication of hedge funds’ general bullish sentiment.

Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns experienced by investors. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 66 percentage points since the end of August 2012. These stocks returned a cumulative of 123.1% vs. 56.5% gain for the S&P 500 Index (read the details). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).

Insider trading at Qorvo Inc (NASDAQ:QRVO) over the past three months was rather bearish, considering that there were 29 sales and no purchases. The sales involved 186,268 shares in total. In a transaction that occurred on July 1, the company’s CEO Robert A. Bruggeworth sold a total of 23,125 shares at an average of $79.77 per share. VP Steven E. Creviston is also reported to have sold a total of 10,000 shares on the same day.

Let’s now have a look at hedge fund activity relating to the stock.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!